Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HBM Holdings Ltd. ( (HK:2142) ) just unveiled an announcement.
HBM Holdings Limited has entered into an exclusive license and equity partnership agreement with Solstice Oncology, under which Solstice receives rights to develop and commercialize the clinical-stage asset HBM4003 outside Greater China. In return, HBM will receive more than US$105 million in upfront and near-term value, including cash and equity in Solstice, and may earn up to about US$1.1 billion in milestone payments plus tiered royalties on future net sales.
The transaction is designed to accelerate HBM4003’s global development by aligning HBM with a venture-backed biotechnology partner while allowing HBM to remain actively involved through its equity stake and collaboration model. The deal strengthens HBM’s international cooperation network and supports long-term value creation without triggering major listing rule obligations, though the company cautions that successful development and commercialization are not assured.
The most recent analyst rating on (HK:2142) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Limited is a biotechnology company focused on developing innovative clinical-stage assets, including its immuno-oncology candidate HBM4003. The group leverages technology platforms and global collaborations to advance therapies, with a particular emphasis on expanding development and commercialization beyond Greater China through strategic partnerships.
Average Trading Volume: 4,207,712
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.46B
See more data about 2142 stock on TipRanks’ Stock Analysis page.